Aura Biosciences offers a classic binary biotech setup: a well-funded, late-stage, vision-preserving oncology platform with major upside if Phase 3 bel-sar data validate its clinical promise.
Overview
Aura Biosciences is a pre-commercial oncology biotech developing virus-like drug conjugates for localized tumor destruction while preserving organ function. Its lead therapy, bel-sar, is in late-stage development for early choroidal melanoma, a rare ocular cancer lacking approved frontline therapies. The platform aims to replace vision-damaging radiotherapy with selective laser-activated tumor ablation and immune stimulation. Aura has no product revenue, but its clinical pipeline spans ophthalmic oncology and NMIBC, positioning the company as a high-risk, high-upside precision oncology platform.